Literature DB >> 14991389

Bone histology in steroid-treated children with non-azotemic nephrotic syndrome.

Michael Freundlich1, Michael Jofe, William G Goodman, Isidro B Salusky.   

Abstract

Patients with nephrotic syndrome (NS) and normal glomerular filtration rate (GFR) frequently exhibit abnormalities of calcium and vitamin D homeostasis, mainly hypocalcemia and reduced circulating vitamin D metabolites. These abnormalities have been linked to alterations of bone histology in adults with non-azotemic NS, particularly osteomalacia and excessive bone resorption. Whether similar abnormalities of bone histology occur in children and adolescents with NS, particularly in those requiring prolonged treatment with corticosteroids, remains largely unknown. Thus, bone histomorphometry and selected bone-modulating hormones were studied in eight children (aged 2-16 years) with normal GFR (range 85-169 ml/min per 1.73 m(2)) and NS. All patients received corticosteroids for at least 12 months prior to bone biopsy. At the time of bone biopsy, the urine protein/creatinine ratio was elevated (2.1+/-3.6), while the average concentrations of parathyroid hormone (36+/-13 pg/ml), 25-hydroxyvitamin D [25(OH) D] (22+/-14 ng/ml), and 1,25(OH)(2)D (59+/-22 pg/ml) were normal. Bone histomorphometry displayed focal osteomalacia (OM) and mild increased bone resorption in most patients. The mineralization lag time, an indicator of the degree of osteomalacia, correlated with the time elapsed since the original diagnosis of NS ( r=0.93, P<0.0005). Overt hyperparathyroidism was not evident, but increased eroded perimeter and elevated bone formation rate (BFR) were evident in two patients, suggesting high-turnover bone disease. The BFR was inversely correlated with the administered dose of prednisone at the time of biopsy ( r=-0.78, P<0.05) and one patient exhibited low bone turnover changes. The growth velocity standard deviation score (SDS) at time of biopsy ranged from -1.6 to 3.2, resulting in a height SDS range of -1.9 to 0.6. The height SDS at time of bone biopsy correlated inversely with the dose of administered glucocorticoid ( r=-0.71, P<0.05) and with the duration of the disease ( r=-0.7, P=0.05). These data, albeit preliminary, demonstrate that children with NS treated with prolonged corticosteroid therapy exhibit bone histopathological changes without a concomitant impairment in GFR. While the OM appears to be related to the disease process, the alterations of bone formation and the adynamic changes are likely the result of the corticosteroid therapy. The potential consequences of these findings on adult bone mass and ultimate height deserve further studies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14991389     DOI: 10.1007/s00467-003-1378-8

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  49 in total

1.  CALCIUM METABOLISM IN NEPHROSIS. I. A DESCRIPTION OF AN ABNORMALITY IN CALCIUM METABOLISM IN CHILDREN WITH NEPHROSIS.

Authors:  K Emerson; W W Beckman
Journal:  J Clin Invest       Date:  1945-07       Impact factor: 14.808

2.  Blood levels of 25-hydroxyvitamin D in nephrotic syndrome. Studies in 26 patients.

Authors:  D A Goldstein; Y Oda; K Kurokawa; S G Massry
Journal:  Ann Intern Med       Date:  1977-12       Impact factor: 25.391

3.  Bone disease in children and adolescents undergoing successful renal transplantation.

Authors:  C P Sanchez; I B Salusky; B D Kuizon; J A Ramirez; B Gales; R B Ettenger; W G Goodman
Journal:  Kidney Int       Date:  1998-05       Impact factor: 10.612

4.  The idiopathic nephrotic syndrome of childhood. A clinical reevaluation of 148 cases.

Authors:  S P Makker; W Heymann
Journal:  Am J Dis Child       Date:  1974-06

5.  Nasal administration of salmon calcitonin for prevention of glucocorticoid-induced osteoporosis in children with nephrosis.

Authors:  T Nishioka; H Kurayama; T Yasuda; J Udagawa; C Matsumura; H Niimi
Journal:  J Pediatr       Date:  1991-05       Impact factor: 4.406

6.  A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure.

Authors:  M R John; W G Goodman; P Gao; T L Cantor; I B Salusky; H Jüppner
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

7.  Absence of metabolic bone disease in adult patients with the nephrotic syndrome and normal renal function.

Authors:  A Korkor; J Schwartz; M Bergfeld; S Teitelbaum; L Avioli; S Klahr; E Slatopolsky
Journal:  J Clin Endocrinol Metab       Date:  1983-03       Impact factor: 5.958

8.  The effect of long- and short-term corticosteroids on plasma calcitonin and parathyroid hormone levels.

Authors:  A T Hattersley; K Meeran; J Burrin; P Hill; R Shiner; H K Ibbertson
Journal:  Calcif Tissue Int       Date:  1994-03       Impact factor: 4.333

9.  Effect of prednisone on growth and bone mineral content in childhood glomerular disease.

Authors:  R W Chesney; R B Mazess; P Rose; D K Jax
Journal:  Am J Dis Child       Date:  1978-08

10.  Vitamin-D metabolism in nephrotic syndrome.

Authors:  J M Barragry; M W France; N D Carter; J A Auton; M Beer; B J Boucher; R D Cohen
Journal:  Lancet       Date:  1977-09-24       Impact factor: 79.321

View more
  13 in total

1.  Bone disease in nephrotic syndrome--prevention is better than cure.

Authors:  Sanjeev Gulati; Kiran Gulati
Journal:  Pediatr Nephrol       Date:  2005-01       Impact factor: 3.714

2.  Pediatric solid organ transplantation and osteoporosis: a descriptive study on bone histomorphometric findings.

Authors:  Inari S Tamminen; Helena Valta; Hannu Jalanko; Sari Salminen; Mervi K Mäyränpää; Hanna Isaksson; Heikki Kröger; Outi Mäkitie
Journal:  Pediatr Nephrol       Date:  2014-02-23       Impact factor: 3.714

3.  Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: general therapy.

Authors:  Yoshitsugu Kaku; Yasufumi Ohtsuka; Yasuhiro Komatsu; Toshiyuki Ohta; Takuhito Nagai; Hiroshi Kaito; Shuji Kondo; Yohei Ikezumi; Seiji Tanaka; Shinsuke Matsumoto; Mayumi Sako; Kazushi Tsuruga; Koichi Nakanishi; Koichi Kamei; Hiroshi Saito; Shuichiro Fujinaga; Yuko Hamasaki; Hiroko Chikamoto; Kenji Ishikura; Kazumoto Iijima
Journal:  Clin Exp Nephrol       Date:  2015-02       Impact factor: 2.801

4.  Free vitamin D levels in steroid-sensitive nephrotic syndrome and healthy controls.

Authors:  Sushmita Banerjee; Surupa Basu; Shakil Akhtar; Rajiv Sinha; Ananda Sen; Jayati Sengupta
Journal:  Pediatr Nephrol       Date:  2019-12-16       Impact factor: 3.714

5.  Inducible podocyte-specific deletion of CTCF drives progressive kidney disease and bone abnormalities.

Authors:  Marta Christov; Abbe R Clark; Braden Corbin; Samy Hakroush; Eugene P Rhee; Hiroaki Saito; Dan Brooks; Eric Hesse; Mary Bouxsein; Niels Galjart; Ji Yong Jung; Peter Mundel; Harald Jüppner; Astrid Weins; Anna Greka
Journal:  JCI Insight       Date:  2018-02-22

6.  Propranolol therapy for infantile hemangioma is less toxic but longer in duration than corticosteroid therapy.

Authors:  Kathryn Sawa; Arjang Yazdani; Michael J Rieder; Guido Filler
Journal:  Plast Surg (Oakv)       Date:  2014       Impact factor: 0.947

Review 7.  Bone Health in Glomerular Kidney Disease.

Authors:  Dorey A Glenn; Michelle R Denburg
Journal:  Curr Osteoporos Rep       Date:  2019-12       Impact factor: 5.096

8.  Vitamin D insufficiency in steroid-sensitive nephrotic syndrome in remission.

Authors:  Francis L Weng; Justine Shults; Rita M Herskovitz; Babette S Zemel; Mary B Leonard
Journal:  Pediatr Nephrol       Date:  2004-11-25       Impact factor: 3.714

9.  Vitamin D in nephrotic syndrome remission: a case-control study.

Authors:  Sushmita Banerjee; Surupa Basu; Jayati Sengupta
Journal:  Pediatr Nephrol       Date:  2013-05-25       Impact factor: 3.714

10.  Biochemical bone markers in nephrotic children.

Authors:  Nese Karaaslan Biyikli; Sevinc Emre; Aydan Sirin; Ilmay Bilge
Journal:  Pediatr Nephrol       Date:  2004-06-17       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.